Nama's AI scorecard currently rates Amylyx Pharmaceuticals Sell (2.7 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does AMLX report earnings?

Amylyx Pharmaceuticals's next scheduled report is on Mar 4, 2027. Analysts expect EPS of -$0.37.

What is the AMLX price target?

The median analyst price target from 11 analysts is $40.00, with a range of $20.00 – $57.00.

Is AMLX Shariah compliant?

Nama's AAOIFI-style screen reads Amylyx Pharmaceuticals as Can't Tell. A figure the screen needs is missing, so it can't tell.

Nama Insights

Amylyx Pharmaceuticals (AMLX)

Healthcare · Drug Manufacturers Specialty Generic · NASDAQ

Amylyx Pharmaceuticals (AMLX) is a Healthcare company in the Drug Manufacturers Specialty Generic industry. It has a market capitalization of $3.70B and a free-cash-flow yield of -4.4%. Over the most recent reported fiscal year, revenue declined 100.0%. Nama's AI scorecard rates it Sell, 2.7 out of 10. On 12-month momentum it ranks in the leading band of its market.

AI scorecard

Sell · 2.7/10

Clearly negative, short of the bottom band. As of Nov 7, 2026.

Momentum

Leading · +120.1% over 12 months ex. last

Top 20% of its market on the past year's steady rise.

Shariah screen

Can't Tell

A figure the screen needs is missing, so it can't tell.

Off its high

-29.6%

How far the last close sits under the highest price of the past five years.

Market cap	$3.70B
Trailing P/E	—
Price / book	13.7
Price / sales	—
FCF yield	-4.4%
Dividend yield	—
Gross margin	0.0%
Operating margin	0.0%
Net margin	0.0%
Revenue growth (YoY)	-100.0%
Revenue growth (3-yr annual)	-100.0%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	-0.1
Exchange	NASDAQ
Sector	Healthcare
Industry	Drug Manufacturers Specialty Generic

AMLX earnings

Next report: Mar 4, 2027 (Q4 2026, EPS estimate -$0.37). Beat the EPS estimate in 1 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 5, 2026	-$0.38	-$0.37	-2.7%	$0
Q2 2026	Aug 6, 2026	-$0.39	-$0.36	-8.3%	$0
Q1 2026	May 7, 2026	-$0.37	-$0.34	-8.8%	$0
Q4 2025	Mar 3, 2026	-$0.30	-$0.34	+11.8%	$0

AMLX analyst price target

Median target $40.00 from 11 analysts, ranging $20.00 – $57.00.

Drug Manufacturers Specialty Generic peers

Ticker	Company	Market cap	P/E
TAK	Takeda Pharmaceutical	$67.16B	42.0
TEVA	Teva Pharmaceutical Industries	$49.72B	18.0
HLN	Haleon	$40.17B	21.3
ZTS	Zoetis	$32.81B	12.0
UTHR	United Therapeutics	$23.94B	21.2
VTRS	Viatris	$22.87B	7.8
NBIX	Neurocrine Biosciences	$16.66B	16.5
ELAN	Elanco Animal Health	$12.86B	24.3

Explore live AMLX data on Nama Insights →

AMLX FAQ

Is AMLX a buy?: Nama's AI scorecard currently rates Amylyx Pharmaceuticals Sell (2.7 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does AMLX report earnings?: Amylyx Pharmaceuticals's next scheduled report is on Mar 4, 2027. Analysts expect EPS of -$0.37.
What is the AMLX price target?: The median analyst price target from 11 analysts is $40.00, with a range of $20.00 – $57.00.
Is AMLX Shariah compliant?: Nama's AAOIFI-style screen reads Amylyx Pharmaceuticals as Can't Tell. A figure the screen needs is missing, so it can't tell.